APA (7th ed.) Citation

Erdemli, G., Murphy, T., & Walinsky, S. Regulatory considerations for successful implementation of digital endpoints in clinical trials for drug development. Nature Portfolio.

Chicago Style (17th ed.) Citation

Erdemli, Gül, Tina Murphy, and Sarah Walinsky. Regulatory Considerations for Successful Implementation of Digital Endpoints in Clinical Trials for Drug Development. Nature Portfolio.

MLA (9th ed.) Citation

Erdemli, Gül, et al. Regulatory Considerations for Successful Implementation of Digital Endpoints in Clinical Trials for Drug Development. Nature Portfolio.